Peritoneal Dialysis Market: as national health systems in China, Southeast Asia, and Latin America adopt PD-first policy frameworks that make peritoneal dialysis the default renal replacement recommendation rather than an alternative to haemodialysis, capacity investment is shifting from a demand-led expansion pace to a policy-led one, so peritoneal dialysis growth in these markets increasingly tracks government programme design and nephrology workforce training investment rather than solely following patient or physician preference.

The global peritoneal dialysis market size was USD 4.26 Billion in 2025 and is expected to register a revenue CAGR of 6.2% during the forecast period. Market revenue growth is driven by factors such as rising global end-stage renal disease prevalence sustaining structural demand for renal replacement therapy, accelerating policy-driven PD-first initiatives in China, Southeast Asia, and Latin America that make peritoneal dialysis the default nephrology programme recommendation, and the modality’s lower capital infrastructure requirement relative to haemodialysis centres supporting rapid capacity expansion in emerging markets. The first driving factor is rising global end-stage renal disease prevalence, sustaining structural demand for renal replacement therapy across all modalities, including peritoneal dialysis specifically. Global end-stage renal disease prevalence continues to rise, driven substantially by increasing diabetes and hypertension prevalence, expanding the total patient population requiring renal replacement therapy across both peritoneal dialysis and haemodialysis modalities. The second driving factor is accelerating policy-driven PD-first initiatives in China, Southeast Asia, and Latin America, converting peritoneal dialysis from an alternative modality into the default nephrology programme recommendation in these markets specifically. National health systems in China, Southeast Asia, and Latin America continue expanding PD-first policy frameworks that position peritoneal dialysis as the preferred initial renal replacement modality, reflecting the therapy’s lower capital infrastructure requirement relative to building and staffing haemodialysis centres at national scale. The third driving factor is peritoneal dialysis’s compatibility with home-based treatment, requiring substantially lower capital infrastructure investment than haemodialysis centres and extending renal replacement therapy access to regions with limited hospital-based dialysis capacity. These are some of the key factors driving revenue growth of the market.

A second layer of demand comes from the way a national PD-first policy framework widens its own addressable patient population as government investment in nephrology training and catheter insertion capacity building compounds over time, letting one policy and training infrastructure investment convert an increasing share of each year’s new end-stage renal disease diagnoses into peritoneal dialysis patients rather than requiring haemodialysis centre capacity to expand at the same pace as diagnosed patient volume. Once a national health system invests in nephrology physician training for PD catheter insertion and establishes supporting policy incentives favouring peritoneal dialysis as the default initial modality, that same training and policy infrastructure continues converting a growing share of newly diagnosed patients to peritoneal dialysis each subsequent year, so policy and training infrastructure investment compounds in effect over time rather than delivering only a one-time capacity increase. As a result, demand and revenue share are concentrating around markets with sustained, multi-year PD-first policy commitment and manufacturers capable of supporting the physician training and catheter insertion capacity building these policies require, and the forecast tilts toward policy-driven capacity expansion in China, Southeast Asia, and Latin America rather than uniform global growth tracking disease prevalence alone. For instance, national health systems across China, Southeast Asia, and Latin America continue to expand PD-first policy frameworks and associated nephrology programme training investment, converting an increasing share of newly diagnosed end-stage renal disease patients to peritoneal dialysis as the default initial modality rather than these markets simply following disease prevalence growth at the same rate as haemodialysis capacity expansion. These are some of the key factors driving revenue growth of the market.

The clearest driver of demand is the sustained rise in global end-stage renal disease prevalence, establishing the underlying patient population base that all renal replacement therapy modalities, including peritoneal dialysis, are designed to serve. Diabetes and hypertension are the two leading causes of chronic kidney disease progression to end-stage renal disease globally, and rising prevalence of both conditions directly expands the population of patients who will eventually require renal replacement therapy, so global diabetes and hypertension prevalence trends and long-run peritoneal dialysis demand are directly and structurally linked. Global end-stage renal disease prevalence continues to rise, driven substantially by increasing diabetes and hypertension prevalence, expanding the total patient population requiring renal replacement therapy across both peritoneal dialysis and haemodialysis modalities globally. The effect on the market is that peritoneal dialysis demand growth has a demand floor tied directly to the scale of global end-stage renal disease prevalence, independent of any single market’s specific PD-first policy commitment. These are some of the key factors driving revenue growth of the market.

The second driver is the acceleration of national PD-first policy frameworks specifically in China, Southeast Asia, and Latin America, converting peritoneal dialysis from a secondary option into the default initial renal replacement modality recommendation. A national health system pursuing PD-first policy makes this choice specifically because peritoneal dialysis requires substantially lower capital infrastructure investment than building and staffing haemodialysis centres at national scale, and this infrastructure cost advantage is what makes PD-first policy an economically rational strategy for health systems seeking to expand renal replacement therapy access without the multi-year capital investment haemodialysis centre construction requires, so lower infrastructure cost and PD-first policy adoption are directly linked. National health systems in China, Southeast Asia, and Latin America continue expanding PD-first policy frameworks that position peritoneal dialysis as the preferred initial renal replacement modality, expanding peritoneal dialysis capacity at nephrology programmes as a home-compatible modality requiring lower capital infrastructure than haemodialysis centres. The effect on the market is that peritoneal dialysis capacity expansion in these specific markets increasingly tracks government policy commitment and nephrology training investment pace rather than patient or physician preference alone. These are some of the key factors driving revenue growth of the market.

“National health systems in China, Southeast Asia, and Latin America continue to expand PD-first policy frameworks that position peritoneal dialysis as the preferred initial renal replacement modality, reflecting the therapy’s substantially lower capital infrastructure requirement relative to building and staffing haemodialysis centres at national scale.”

The third driver is peritoneal dialysis’s fundamental compatibility with home-based treatment delivery, requiring substantially lower capital infrastructure investment than building and staffing haemodialysis centres. A haemodialysis centre requires dedicated facility space, specialised water treatment infrastructure, and trained dialysis nursing staff at each treatment location, while peritoneal dialysis shifts most of this infrastructure requirement to the patient’s home with periodic nephrology programme oversight, and this structural difference is what allows peritoneal dialysis to extend renal replacement therapy access to regions where building comprehensive haemodialysis centre infrastructure would take substantially longer and cost substantially more. Peritoneal dialysis’s home-compatible delivery model directly addresses the capacity constraint that limited hospital-based dialysis infrastructure creates in regions where comprehensive haemodialysis centre networks have not yet been built. The effect on the market is that peritoneal dialysis is capturing a growing share of new renal replacement therapy capacity specifically in regions where haemodialysis centre infrastructure remains limited relative to diagnosed patient population. These are some of the key factors driving revenue growth of the market.

However, the peritoneal dialysis market faces adoption constraints from peritonitis infection risk and technique failure from catheter dysfunction, limited physician training in PD catheter insertion outside specialist nephrology centres in lower-income markets, and the continued dominance of haemodialysis as the established default renal replacement modality globally. Because peritoneal dialysis carries an inherent peritonitis infection risk and technique failure risk from catheter dysfunction, both genuine clinical complications that can require modality switching to haemodialysis, some patients and physicians continue to favour haemodialysis despite peritoneal dialysis’s home-compatibility and lower infrastructure requirement advantages, and this clinical risk profile means peritoneal dialysis adoption depends on nephrology programmes having the infection prevention and catheter management protocols in place to minimise these risks. Limited physician training in PD catheter insertion outside specialist nephrology centres is a second constraint, because peritoneal dialysis catheter placement requires specific procedural training that is not uniformly available, particularly in lower-income markets where nephrology specialist density remains limited, meaning even where PD-first policy exists on paper, the physician workforce capacity to execute catheter insertion at the volume required may lag policy ambition. Haemodialysis modality dominance is the third constraint, since haemodialysis remains the dominant renal replacement modality globally by installed treatment centre count and established nephrology programme referral pattern, and converting established referral patterns and patient preference toward peritoneal dialysis requires sustained policy and education investment that not every market has committed to at the scale China, Southeast Asia, and Latin America are currently demonstrating. These factors substantially limit peritoneal dialysis market growth over the forecast period.

Based on product, the global peritoneal dialysis market is segmented into PD solutions/dialysate, PD catheters, and automated PD cyclers. PD solutions/dialysate hold the largest revenue share, because they represent the recurring, per-treatment consumable required for every peritoneal dialysis exchange regardless of modality, which suits the category’s structural link to overall PD patient population growth. Automated PD cyclers are expected to register the fastest revenue growth rate in the global peritoneal dialysis market over the forecast period, driven by the shift toward automated peritoneal dialysis modality within PD-first policy markets, which is why cycler technology represents the fastest-evolving product category within the broader market.

Continuous ambulatory peritoneal dialysis (CAPD) modality is expected to account for a significantly large revenue share in the global peritoneal dialysis market during the forecast period

Based on modality, the global peritoneal dialysis market is segmented into continuous ambulatory peritoneal dialysis (CAPD) and automated peritoneal dialysis (APD). CAPD holds a significant revenue share, reflecting its lower equipment cost and established role as the initial peritoneal dialysis modality in many PD-first policy programmes, particularly in resource-constrained markets prioritising rapid capacity expansion. APD is expected to register the fastest revenue growth rate in the global peritoneal dialysis market over the forecast period, driven by rising preference for overnight automated treatment that minimises daytime treatment burden, which is why automated cycler adoption continues to expand alongside CAPD’s established base.

Based on end-use, the global peritoneal dialysis market is segmented into home care and hospital-based nephrology programmes. Home care holds the largest revenue share, reflecting peritoneal dialysis’s fundamental design as a home-compatible renal replacement modality, which suits the therapy’s core value proposition relative to centre-based haemodialysis. Hospital-based nephrology programmes remain essential for PD catheter insertion, patient training, and ongoing clinical oversight, representing a smaller but structurally necessary revenue category supporting the broader home care patient population.

Based on regional analysis, the peritoneal dialysis market in North America accounted for largest revenue share in 2025. The United States leads because it hosts a large, established end-stage renal disease patient population and because Vantive (formerly Baxter Kidney Care) and Fresenius Medical Care both concentrate significant commercial and product development activity in the country. Vantive’s February 2025 FDA correction for its MiniCap Extended Life Peritoneal Dialysis Transfer Sets, addressing potential toxic compound exposure risk, reflects the scale of regulatory oversight and quality system activity concentrated in the United States peritoneal dialysis market specifically. The concentration of leading peritoneal dialysis manufacturers and FDA regulatory activity in the United States also means new peritoneal dialysis product technology and safety corrections are typically addressed in the United States first.

The market in Europe is expected to register a steady revenue growth rate over the forecast period. Germany, the United Kingdom, and France represent the three largest national peritoneal dialysis markets within Europe. The region’s established nephrology programme infrastructure and national health system reimbursement structures sustain steady demand. The result is steady rather than rapid growth, shaped more by the region’s already-mature nephrology infrastructure than by the policy-driven expansion dynamics currently active in China, Southeast Asia, and Latin America.

The market in Asia Pacific is expected to register the fastest revenue growth rate of any region over the forecast period. China, Japan, and India represent the three largest national peritoneal dialysis markets within the region, with China specifically implementing extensive PD-first national policy initiatives. Accelerating policy-driven PD-first capacity expansion in China, combined with rising diabetes-driven end-stage renal disease prevalence, is driving new peritoneal dialysis demand from a comparatively lower installed base than North America and Europe.

The market in Latin America is expected to register a rapid revenue growth rate over the forecast period. Brazil and Mexico represent the two largest national peritoneal dialysis markets within the region, both pursuing PD-first policy initiatives to expand renal replacement therapy access. The indirect effects of Iran-US sanctions and the associated Strait of Hormuz shipping disruption have kept freight and import costs elevated for the specialised PD solutions and catheters that Latin American nephrology programmes depend on through 2026, moderating the pace of policy-driven capacity expansion despite strong underlying government commitment.

The market in Middle East and Africa is expected to register a moderate revenue growth rate over the forecast period. Saudi Arabia and the UAE represent the primary commercial peritoneal dialysis markets within the GCC. The UAE is the most established peritoneal dialysis market on the continent given its concentrated private hospital nephrology infrastructure, while the wider Gulf states and broader African markets are still building the nephrology physician training capacity that PD catheter insertion and programme expansion depend on.